Dipyrone, hyoscine-n-butyl (Buscopan Compositum)
Dipyrone, hyoscine-n-butyl
Opella Healthcare South Africa (Pty) Ltd
Registration
- Applicant
- Opella Healthcare South Africa (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Buscopan compositum 10 mg/250 MG EACH TABLET CONTAINS DIPYRONE 250 mg HYOSCINE-N-BUTYL BROMIDE 10 mg | 10 mg/250 mg | E0502E/11.2/502 | Registered | Not determined | None |
| Buscopan compositum 20 mg/2,5 g EACH 5,0l SOLUTTION CONTAINS DIPYRONE 2500,0g HYOSCINE-N-BUTYL BROMIDE 20,0g | 20 mg/2,5 g | E0504E/11.2/504 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.